More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

Please provide your email address to receive an email when new articles are posted on . New data show that rapid initiation with once-monthly Sublocade significantly improved treatment retention vs.

Extended-release 7-day injectable buprenorphine was safe and tolerable for most patients who had minimal-to-mild opioid withdrawal, a nonrandomized trial found. Among 100 adult patients with ...

Extended-release injectable buprenorphine (XR-BUP) in patients with opioid overdose can allow more time to access follow-up care while providing continued medication for a longer duration, according ...

About The Study: In this multicenter randomized clinical trial, rapid induction had higher retention than standard induction overall and in patients who tested positive for fentanyl through ...

Hospira, Inc., a Pfizer company (“Pfizer”), is voluntarily recalling the lots listed in the table below of Buprenorphine Hydrochloride Injection CarpujectTM Units and Labetalol Hydrochloride Injection ...

BRAINERD — Once an inmate is undergoing opioid treatment in custody, is there a way to help them upon release? Crow Wing County officials believe so and credit a drug that is administered once a month ...

Injectable, extended-release buprenorphine was deemed safe for patients experiencing minimal to mild opioid withdrawal (COWS scores 4-7), making the drug a viable and safe treatment option, according ...